Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06618287 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
416
Enrollment target
20
Study locations

NCT06618287 is a Phase 1 study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 416 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06618287, a Phase 1 study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
416 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Conditions Studied

Breast Cancer Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Osimertinib
  • DRUG Nivolumab
  • DRUG Pumitamig
  • DRUG BMS-986507

Study Locations (20)

Ohio

  • Cleveland Clinic - Cleveland
  • Local Institution - 0102 - Columbus

Oregon

  • Local Institution - 0052 - Portland
  • Local Institution - 0090 - Portland

Ontario

  • Local Institution - 0064 - Newmarket
  • Local Institution - 0023 - Ottawa

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • University of Miami Hospital and Clinics, Sylvester Cancer Center - Miami

Illinois

  • Local Institution - 0125 - Maywood

Iowa

  • Local Institution - 0065 - Iowa City

New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center - Hackensack

Trial Details

FieldValue
Enrollment Target 416 participants
Start Date 2025-02-04
Est. Completion 2031-02-26
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06618287

The ClinicalTrials.gov registry entry for NCT06618287 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06618287 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Ohio, Oregon, Ontario.

Frequently Asked Questions

What is clinical trial NCT06618287 about?

NCT06618287 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

What is the current status of trial NCT06618287?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 416 participants. The study started on 2025-02-04. Estimated completion is 2031-02-26.

What conditions does trial NCT06618287 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer.

What interventions are being tested in trial NCT06618287?

The interventions under investigation include: Pembrolizumab (DRUG), Osimertinib (DRUG), Nivolumab (DRUG), Pumitamig (DRUG), BMS-986507 (DRUG).

Who is sponsoring clinical trial NCT06618287?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06618287 being conducted?

This trial has 20 study locations across Alabama, Florida, Illinois, Iowa, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.